tag:blogger.com,1999:blog-5037190876571380696.post6362900268142711044..comments2023-11-25T03:11:51.759-06:00Comments on On Today's Page: Time to break up medical monopolies of our own making?Denis Drewhttp://www.blogger.com/profile/11833367196756465896noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-5037190876571380696.post-55003068888524265342015-06-09T10:22:43.626-05:002015-06-09T10:22:43.626-05:00HEADLINE:
Organ transplant medication could prot...HEADLINE: <br />Organ transplant medication could protect against Alzheimer's<br /><br />"While 11% of the general population of patients over 65 years had dementia, only 1.02% of the study subjects of the same age had the disease. Similarly, 15.3% of the American population over 75 years had Alzheimer's compared with only 0.6% of the study participants."<br /><br />http://www.medicalnewstoday.com/articles/295047.phpDenis Drewhttps://www.blogger.com/profile/11833367196756465896noreply@blogger.comtag:blogger.com,1999:blog-5037190876571380696.post-58488259978881252602015-05-25T14:01:30.589-05:002015-05-25T14:01:30.589-05:00About the idea of government regulating drug costs...About the idea of government regulating drug costs; not too radical, theoretically government can do it right now ...<br /><br />... from The Truth About Drug Companies (p. 68-69) by Marcia Angell (former editor-in-chief of the New England Journal of Medicine).<br />http://www.amazon.com/The-Truth-About-Drug-Companies/dp/0375760946<br /><br />"There ought to be a law -- and there is<br />"... First, under exceptional circumstances which are vaguely defined in terms of serving the public interest, the NIH may require that work it supports in medical schools, teaching hospitals and small biotechnology companies not be patented but remain in the public domain.<br />"Second, Bayh-Dole requires that work licensed to drug companies 'be made available to the public on reasonable terms.'<br />"Fourth, the government retains the right to 'march in' and use a licensed drug itself or issue compulsory licenses to other companies if the original company is not fulfilling its obligations."<br /><br />She says: "All of these provisions have been pretty much ignored by both industry and academia."Denis Drewhttps://www.blogger.com/profile/11833367196756465896noreply@blogger.com